{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:27:15Z","timestamp":1787506035614,"version":"build-2736575974"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Res Notes"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1186\/1756-0500-7-614","type":"journal-article","created":{"date-parts":[[2014,9,7]],"date-time":"2014-09-07T21:02:24Z","timestamp":1410123744000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Comparison of anti-anaerobic antimicrobial strategies in cancer patients with febrile neutropenia and gastrointestinal symptoms"],"prefix":"10.1186","volume":"7","author":[{"given":"Regis G","family":"Rosa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo P","family":"dos Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciano Z","family":"Goldani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,9,8]]},"reference":[{"issue":"3","key":"3125_CR1","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1086\/322595","volume":"33","author":"RL Lark","year":"2001","unstructured":"Lark RL, McNeil SA, VanderHyde K, Noorani Z, Uberti J, Chenoweth C: Risk factors for anaerobic bloodstream infections in bone marrow transplant recipients. Clin Infect Dis. 2001, 33 (3): 338-343. 10.1086\/322595.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"3125_CR2","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1097\/QCO.0b013e3283630dd3","volume":"26","author":"Y Taur","year":"2013","unstructured":"Taur Y, Pamer EG: The intestinal microbiota and susceptibility to infection in immunocompromised patients. Curr Opin Infect Dis. 2013, 26 (4): 332-337. 10.1097\/QCO.0b013e3283630dd3. doi:10.1097\/QCO.0b013e3283630dd3","journal-title":"Curr Opin Infect Dis"},{"issue":"1","key":"3125_CR3","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s15010-012-0389-4","volume":"41","author":"JT Ngo","year":"2013","unstructured":"Ngo JT, Parkins MD, Gregson DB, Pitout JD, Ross T, Church DL, Laupland KB: Population-based assessment of the incidence, risk factors, and outcomes of anaerobic bloodstream infections. Infection. 2013, 41 (1): 41-48. 10.1007\/s15010-012-0389-4. doi:10.1007\/s15010-012-0389-4","journal-title":"Infection"},{"issue":"3","key":"3125_CR4","first-page":"243","volume":"42","author":"CW Cheng","year":"2009","unstructured":"Cheng CW, Lin HS, Ye JJ, Yang CC, Chiang PC, Wu TS, Lee MH: Clinical significance of and outcomes for bacterioides fragilis bacteremia. J Microbiol Immunol Infect. 2009, 42 (3): 243-250.","journal-title":"J Microbiol Immunol Infect"},{"issue":"3","key":"3125_CR5","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.anaerobe.2011.05.013","volume":"17","author":"J Papaparaskevas","year":"2011","unstructured":"Papaparaskevas J, Katsandri A, Pantazatou A, Stefanou I, Avlamis A, Legakis NJ, Tsakris A: Epidemiological characteristics of infections caused by Bacterioides, Prevotella and Fusobacterium species: aprospective observational study. Anaerobe. 2011, 17 (3): 113-117. 10.1016\/j.anaerobe.2011.05.013. doi:10.1016\/j.anaerobe.2011.05.013","journal-title":"Anaerobe"},{"issue":"7","key":"3125_CR6","doi-asserted-by":"publisher","first-page":"3799","DOI":"10.1128\/AAC.02561-14","volume":"58","author":"RG Rosa","year":"2014","unstructured":"Rosa RG, Goldani LZ: Cohort study of the impact of time to antibiotic administration on mortality in patients with febrile neutropenia. Antimicrob Agents Chemother. 2014, 58 (7): 3799-803. 10.1128\/AAC.02561-14. doi:10.1128\/AAC.02561-14","journal-title":"Antimicrob Agents Chemother"},{"key":"3125_CR7","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1186\/1471-2334-14-286","volume":"14","author":"RG Rosa","year":"2014","unstructured":"Rosa RG, Goldani LZ, dos Santos RP: Association between adherence to an antimicrobial stewardship program and mortality among hospitalized cancer patients with febrile neutropaenia: a prospective cohort study. BMC Infect Dis. 2014, 14: 286-10.1186\/1471-2334-14-286. doi:10.1186\/1471-2334-14-286","journal-title":"BMC Infect Dis"},{"key":"3125_CR8","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.1093\/cid\/cir073","volume":"52","author":"AG Freifeld","year":"2011","unstructured":"Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, Raad II, Rolston KV, Young JA, Wingard JR: Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2011, 52: e56-e93. 10.1093\/cid\/cir073. doi:10.1093\/cid\/cir073","journal-title":"Clin Infect Dis"},{"key":"3125_CR9","doi-asserted-by":"publisher","first-page":"v252","DOI":"10.1093\/annonc\/mdq196","volume":"21","author":"J De Naurois","year":"2010","unstructured":"De Naurois J, Novitzky-Basso I, Gill MJ, Marti FM, Cullen MH, Roila F, ESMO Gguidelines Working Group: Management of febrile neutropenia: ESMO clinical practice guidelines. Ann Oncol. 2010, 21: v252-v256. 10.1093\/annonc\/mdq196. doi:10.1093\/annonc\/mdq196","journal-title":"Ann Oncol"},{"issue":"16","key":"3125_CR10","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1200\/JCO.2000.18.16.3038","volume":"18","author":"J Klastersky","year":"2000","unstructured":"Klastersky J, Paesmans M, Rubenstein EB, Boyer M, Elting L, Feld R, Gallagher J, Herrstedt J, Rapoport B, Rolston K, Talcott J: The Multinational Association for Supportive Care in Cancer Risk Index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol. 2000, 18 (16): 3038-3051.","journal-title":"J Clin Oncol"},{"key":"3125_CR11","volume-title":"Performance Standards for Antimicrobial Susceptibility Testing: Twenty-Second Informational Supplement. M100-S22","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2012","unstructured":"Clinical and Laboratory Standards Institute (CLSI): Performance Standards for Antimicrobial Susceptibility Testing: Twenty-Second Informational Supplement. M100-S22. 2012, Wayne, PA"},{"issue":"3","key":"3125_CR12","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s15010-007-6237-2","volume":"35","author":"J Garbino","year":"2007","unstructured":"Garbino J, Villiger P, Caviezel A, Matulionyte R, Uckay I, Morel P, Lew D: A randomized prospective study of cefepime plus metronidazole with imipenem-cilastatin in the treatment of intra-abdominal infections. Infection. 2007, 35 (3): 161-166. 10.1007\/s15010-007-6237-2.","journal-title":"Infection"},{"issue":"12","key":"3125_CR13","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1001\/archsurg.1997.01430360040008","volume":"132","author":"PS Barie","year":"1997","unstructured":"Barie PS, Vogel SB, Dellinger EP, Rotstein OD, Solomkin JS, Yang JY, Baumgartner TF: A randomized, double-blind clinical trial comparing cefepime plus metronidazole with imipenem-cilastatin in the treatment of complicated intra-abdominal infections. Cefepime Intra-Abdominal Infection Study Group. Arch Surg. 1997, 132 (12): 1294-1302. 10.1001\/archsurg.1997.01430360040008.","journal-title":"Arch Surg"},{"key":"3125_CR14","doi-asserted-by":"publisher","first-page":"S16","DOI":"10.1086\/647939","volume":"50","author":"S L\u00f6fmark","year":"2010","unstructured":"L\u00f6fmark S, Edlund C, Nord CE: Metronidazole is still the drug of choice for treatment of anaerobic infections. Clin Infect Dis. 2010, 50: S16-S23. 10.1086\/647939. doi:10.1086\/647939","journal-title":"Clin Infect Dis"}],"container-title":["BMC Research Notes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1756-0500-7-614.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T01:37:10Z","timestamp":1630546630000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcresnotes.biomedcentral.com\/articles\/10.1186\/1756-0500-7-614"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9,8]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["3125"],"URL":"https:\/\/doi.org\/10.1186\/1756-0500-7-614","relation":{},"ISSN":["1756-0500"],"issn-type":[{"value":"1756-0500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9,8]]},"assertion":[{"value":"15 August 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"614"}}